Carlos G. Santos‐Gallego

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, Rodolfo San Antonio et al. · Journal of the American College of Cardiology · 2019 · 633 citations

Myocardial Energetics, Cardiomyopathy, Heart Failure +8

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

Carlos G. Santos‐Gallego, Ariana P. Vargas-Delgado, Juan Antonio Requena-Ibáñez et al. · Journal of the American College of Cardiology · 2020 · 492 citations

Diabetes Management, Heart Failure, Cardiovascular Disease +7

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF

Juan Antonio Requena-Ibáñez, Carlos G. Santos‐Gallego, Anderly Rodriguez-Cordero et al. · JACC Heart Failure · 2021 · 244 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +10

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure

Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, Rodolfo San Antonio et al. · JACC. Cardiovascular imaging · 2020 · 183 citations

Metabolic Syndrome, Left Ventricular Fibrosis/stiffness, Heart Failure +9

Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion

Carlos G. Santos‐Gallego, Torsten Vahl, Georg Goliasch et al. · Circulation · 2016 · 168 citations · Full text